Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment ...

Stocks to Buy or Sell. In this article, we are going to take a look at where Cardinal Health, Inc. (NYSE:CAH) stands against ...

Healthcare distributor and services company Cardinal Health (NYSE:CAH) beat Wall Street’s revenue expectations in Q4 CY2024, ...

Q2 2025 Earnings Call Transcript January 30, 2025 Cardinal Health, Inc. beats earnings expectations. Reported EPS is $1.93, ...

Bank of America Securities analyst Allen Lutz maintained a Buy rating on Cardinal Health (CAH – Research Report) today. The company’s shares ...

Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday.Invest with ...

Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...

Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...

Cardinal Health (NYSE:CAH – Get Free Report) had its target price hoisted by equities researchers at Wells Fargo & Company from $127.00 to $135.00 in a research note issued on Wednesday,Benzinga ...

Cardinal Health Inc (CAH) stock saw a decline, ending the day at $127.73 which represents a decrease of $-3.00 or -2.29% from the prior close of $130.73. The stock opened at $130.84 and touched a low ...

According to the average brokerage recommendation (ABR), one should invest in Cardinal (CAH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...